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SUMMARY
Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to 
corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an 
anti-IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with 
relapsed or refractory multiple myeloma who had ≥2 prior lines of therapy, one of which had to be 
bortezomib-based. Fourteen initial patients received siltuximab alone, 10 of whom had 
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dexamethasone added for suboptimal response; 39 subsequent patients were treated with 
concurrent siltuximab and dexamethasone. Patients received a median of 4 prior lines of therapy, 
83% were relapsed and refractory, and 70% refractory to their last dexamethasone-containing 
regimen. Suppression of serum C-reactive protein levels, a surrogate marker of IL6 inhibition, was 
demonstrated. There were no responses to siltuximab but combination therapy yielded a partial 
(17%) + minimal (6%) response rate of 23%, with responses seen in dexamethasone-refractory 
disease. The median time to progression, progression-free survival and overall survival for 
combination therapy was 4.4, 3.7 and 20.4 months, respectively. Haematological toxicity was 
common but manageable. Infections occurred in 57% of combination-treated patients, including 
≥grade 3 infections in 18%. Further study of siltuximab in modern corticosteroid-containing 
myeloma regimens is warranted, with special attention to infection-related toxicity.
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Introduction
Although the advent of the immunomodulatory drugs, thalidomide and lenalidomide, the 
proteasome inhibitor bortezomib, and autologous stem cell transplantation has significantly 
improved outcomes for patients with multiple myeloma, the majority of patients will 
experience repeated relapses and ultimately succumb to refractory disease (Kumar, et al 
2004). As such, novel therapies are needed for this patient population.
Interleukin-6 (IL6) is a pleiotropic cytokine that has been shown to play a critical role in the 
pathogenesis of multiple myeloma (Anderson, et al 1989, Kawano, et al 1988, Klein, et al 
1989, Uchiyama, et al 1993). Pre-clinical studies have demonstrated that IL6 not only 
contributes to multiple myeloma cell proliferation and survival but also to resistance to 
chemotherapeutics, including bortezomib and melphalan (Hunsucker, et al 2011, Voorhees, 
et al 2007). In particular, IL6 conferred striking resistance to corticosteroid-induced 
apoptosis (Chauhan, et al 1997, Hardin, et al 1994, Juge-Morineau, et al 1995, Lichtenstein, 
et al 1995, Rowley, et al 2000). Although multiple growth factors have been implicated in 
corticosteroid resistance (Ferlin-Bezombes, et al 1998, Juge-Morineau, et al 1995, Liu, et al 
1999, Moreaux, et al 2004, Xu, et al 1997), inhibition of IL6 was able to sensitize multiple 
myeloma cells to dexamethasone-induced cell death even when grown in the presence of 
bone marrow stromal cells (Cheung and Van Ness 2001, Grigorieva, et al 1998, Honemann, 
et al 2001). Additionally, studies in the severe combined immunodeficient mouse-human 
(SCID-hu) chimera mouse model of human multiple myeloma have also demonstrated 
synergistic activity between anti-IL6 therapy and dexamethasone (Fulciniti, et al 2009, 
Tassone, et al 2005). As such, inhibition of IL6 is an attractive approach to the treatment of 
multiple myeloma, particularly as a way of overcoming corticosteroid resistance.
Siltuximab is a chimeric monoclonal antibody with strong affinity and specificity for human 
IL6. We have previously demonstrated strong synergistic activity of siltuximab and 
dexamethasone in multiple myeloma cell lines grown in the presence of bone marrow stroma 
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and in patient multiple myeloma cells, including those derived from patients with 
corticosteroid-resistant disease (Voorhees, et al 2009). An early phase 1 study evaluated 
escalating doses of siltuximab in patients with relapsed or relapsed and refractory multiple 
myeloma who had received at least 2 prior lines of chemotherapy (van Zaanen, et al 1998). 
Siltuximab was given as 14 daily 2-hour infusions on a 28-day cycle for a maximum of 2 
cycles. The median half-life of siltuximab was 17.8 days, and no human anti-chimeric 
antibodies were noted. C-reactive protein (CRP), a surrogate marker of IL6 activity, 
decreased to undetectable levels in 11 of 12 patients. Treatment was well tolerated but no 
responses were seen. More recently, another phase 1 dose escalation study of single-agent 
siltuximab was conducted in patients with B-cell non-Hodgkin lymphoma, Castleman 
disease, or multiple myeloma utilizing an intermittent dose schedule (i.e., weekly, every 2 
weeks or every 3 weeks). Treatment was well tolerated, even after prolonged dosing, and no 
dose-limiting toxicities were seen (Kurzrock, et al 2011). Clinical activity was encouraging 
in multicentric Castleman disease, with 8 of 11 patients treated at the highest dose level of 
12 mg/kg every 2 or 3 weeks experiencing a radiological response and all patients deriving 
clinical benefit (van Rhee, et al 2010). Of the 13 patients with multiple myeloma on that 
study, 2 achieved complete responses and 1 had prolonged stabilization of disease 
(Kurzrock, et al 2011).
Given the pre-clinical and preliminary clinical data, we conducted an open-label multicentre, 
single-arm phase 2 study to evaluate the efficacy and safety of siltuximab, both as a single 
agent and in combination with dexamethasone, for patients with bortezomib-pretreated 
multiple myeloma relapsing after or refractory to at least 2 prior lines of therapy.
Methods
Patients
Study patients were at least 18 years of age and had received ≥2 prior lines of therapy, with 
documented relapse after or progression on the last line of therapy. Prior therapy with a 
bortezomib-containing regimen was required. Other eligibility criteria included measurable 
disease, an Eastern Cooperative Oncology Group performance status of ≤2, adequate bone 
marrow reserves (absolute neutrophil count ≥1.0 × 109/l, haemoglobin ≥75 g/l and platelet 
count ≥50 × 109/l), adequate liver function (aspartate aminotransferase, alanine 
aminotransferase and alkaline phosphatase levels ≤3 times the upper limit of normal, total 
bilirubin ≤2 times the upper limit of normal), and a calculated creatinine clearance of ≥20 
ml/min. Patients of childbearing potential were required to use adequate birth control 
measures, and female patients of childbearing potential had to have a negative serum 
pregnancy test at the time of screening.
Patients provided written informed consent before study entry. Each of the participating 
centres obtained approval through their Institutional Review Boards or Ethical Committees, 
and the study was conducted in accordance with the Declaration of Helsinki.
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Study design and treatment
The study included 2 treatment plans, A and B. Patients on treatment plans A and B received 
siltuximab (Janssen Biotech, Inc., Horsham, PA, USA) at a dose of 6 mg/kg on day 1 and 15 
of a 28-day cycle as a 2-h intravenous infusion. The rationale for the dose and schedule was 
based on pharmacokinetic and pharmacodynamic modelling from a 3-part phase 1/2 study of 
siltuximab in metastatic renal cell carcinoma, which revealed that a dose of 6 mg/kg once 
every 2 weeks would decrease CRP levels throughout the duration of the treatment period 
(Puchalski, et al 2010). For treatment plan A, pulse dexamethasone was added after cycle 1 
for disease progression and after cycle 2 for less than a partial response. If no partial 
responses or better were seen with single-agent siltuximab in the first 14 patients on 
treatment plan A, subsequent patients would be treated per treatment plan B, in which 
siltuximab and pulse dexamethasone were administered concurrently beginning with cycle 1 
of treatment. Pulse dexamethasone consisted of 40 mg on days 1 − 4, 9 − 12, and 17 − 20 for 
the first four 28-day cycles and days 1 − 4 thereafter. Prophylactic antibiotic therapy (e.g. 
trimethoprim-sulfamethoxazole) was required for the duration of dexamethasone therapy. 
The planned duration of treatment was 12 cycles; however, patients with stable disease or 
better were allowed to remain on therapy beyond 12 cycles. Siltuximab was not dose 
reduced during treatment. However prior to re-dosing, the absolute neutrophil count had to 
be ≥0.5 × 109/l, haemoglobin ≥75 g/l, and platelet count ≥50 × 109/l, and all other clinically-
significant toxicity had to recover to ≤grade 2 or baseline. Siltuximab treatment could be 
delayed up to 14 days; no more than 2 toxicity-related dose delays were allowed. 
Dexamethasone could be stepwise dose reduced to a minimum of 20 mg on days 1-4 in the 
presence of steroid-induced toxicity.
Data were collected and analysed by medical and statistical representatives from Janssen 
Research & Development and the investigators. All investigators had access to the primary 
data and participated in the preparation of the manuscript. Participating institutions received 
clinical grant support for the conduct of the study.
Assessment of efficacy
The primary efficacy endpoint was the overall response rate (≥partial response rate), as per 
European Group for Blood and Marrow Transplant (EBMT) criteria (Blade, et al 1998), to 
either single-agent siltuximab or the combination of siltuximab and dexamethasone, 
depending on whether treatment plan A or B was utilized. Patients were evaluable for 
response if they received at least one dose of siltuximab and had at least one confirmed post-
baseline disease assessment. Response was assessed on day 22 of each cycle by the 
investigator using M-protein results from a central laboratory, and confirmed by the sponsor. 
Secondary efficacy endpoints included time to response, duration of response, time to 
progression, progression-free survival and overall survival. Minimal responses were also 
evaluated, due to its proven clinical benefit in this patient population (Anderson, et al 2008, 
Niesvizky, et al 2008). An assessment of overall response rate utilizing the International 
Myeloma Working Group (IMWG) uniform response criteria was also performed (Durie, et 
al 2006).
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Time to response was defined as the time from the first administration of protocol therapy to 
the time of first confirmed response. Duration of response was defined as the time from the 
first documented response to the time of first documented disease progression. Time to 
progression was defined as the time interval from the first administration of protocol therapy 
to first documented disease progression. Progression-free survival was defined as the time 
interval from the first administration of protocol therapy to first documented disease 
progression or death, whichever occurred first. Relapsed and refractory disease was defined 
as disease that is nonresponsive while on therapy or progresses within 60 days of the last 
dose of therapy in patients who have achieved ≥minimal response at some point in their 
disease course (Anderson, et al 2008, Rajkumar, et al 2011). Dexamethasone-refractory 
disease was defined as less than a minimal response to any prior dexamethasone-containing 
therapy or disease progression within 60 days of completing the last dexamethasone-based 
therapy.
Assessment of safety, pharmacokinetic, pharmacodynamic and biomarker end points
Patients who received ≥1 dose of siltuximab were evaluable for safety. Adverse events were 
assessed at each study visit and graded for intensity per National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 3.0. (http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/ctcaev3.pdf). Adverse events were 
recorded from the time of obtaining informed consent to 30 days after administration of the 
last study agent. Safety endpoints included the incidence of all adverse events, ≥grade 3 
adverse events, serious adverse events, deaths, and clinically-significant changes in vital 
signs, safety-related laboratory parameters and electrocardiograms.
Serum samples for pharmacokinetic evaluation of siltuximab were obtained pre- and post-
dose on day 1 and on day 8 of cycles 1 − 3. Siltuximab serum concentrations were 
determined using an electrochemiluminescent immunoassay format on the Meso Scale 
Discovery Platform with a lower limit of quantification of 0.045 μg/ml. Serum samples to 
evaluate anti-siltuximab antibodies were obtained at baseline, the time of siltuximab 
discontinuation, and every 3 months up to 3 times after the last dose. Antibodies to 
siltuximab were determined using a validated assay (Rossi, et al 2010). CRP levels were 
drawn with each siltuximab administration for cycles 1 − 3 and on day 1 of each subsequent 
cycle. Exploratory pharmacodynamic markers, including but not limited to hepcidin, were 
obtained on day 1 of cycles 1 − 3. CRP was analysed at a central laboratory. Hepcidin was 
tested using a polyclonal antibody-based competitive enzyme-linked immunosorbent assay 
(Intrinsic LifeSciences, LLC, La Jolla, CA, USA).
Statistical analysis
The original sample size was 40 patients. The study was later amended to allow enrollment 
of a total of 90 patients to better estimate the response rate with greater precision. Due to 
slow accrual, the study was closed after enrollment of 55 patients. No formal hypothesis 
testing was planned. Descriptive statistics were used to summarize the data. For continuous 
parameters, number of observations, mean, standard deviation, median and range were used. 
For discrete parameters, frequency was summarized. Time-to-event endpoints were 
evaluated as per the Kaplan-Meier method. Efficacy and safety data were analysed 
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separately for those receiving treatment plan A and B. In addition, data from patients who 
received dexamethasone in treatment plan A were combined with treatment plan B to 
provide a more comprehensive assessment of efficacy and safety with the combination of 
siltuximab and dexamethasone. For those patients on treatment plan A who received 
dexamethasone, time-to-event analyses were performed from the time that combination 
therapy was initiated. Ad-hoc comparison of some specific baseline characteristics were 
conducted between treatment plans A and B based on Fisher’s exact test. The differences 
were tested at a two-sided alpha level of 0.05.
Results
Patient and treatment information
All patients had completed protocol therapy at the time of data cut-off. From September 
2006 to May 2009, a total of 55 patients with relapsed or refractory multiple myeloma were 
enrolled at 10 treatment centres in the United States and The Netherlands. Two patients were 
not treated on study: one due to the development of an adverse event; the other due to 
ineligibility. Fourteen patients were treated with single agent siltuximab per treatment plan 
A, 4 of whom had dexamethasone added to their therapy after cycle 1 and 6 after cycle 2 for 
lack of response. Thirty-nine patients were treated with concurrent siltuximab and 
dexamethasone beginning with cycle 1. In all treated patients, the median number of 
treatment cycles administered was 4 (range 1 – 24). Thirty-two patients (60%) received 1 – 4 
cycles, 11 patients (21%) received 5 – 8 cycles, 8 patients (15%) received 9 − 12 cycles, and 
2 patients (4%) received greater than 12 cycles. Of the 53 patients treated with siltuximab, 
37 (70%) discontinued therapy due to disease progression, 12 (23%) due to adverse events, 
and 4 (8%) for other reasons. The median age of all treated patients was 65 years (range 43 – 
89), and the median time from diagnosis was 4.0 years (range 0.7 – 13.2) (Table I). The 
median beta2-microglobulin was 4.2 mg/l (range 1.3 – 15.6), and 37% and 29% of patients 
had International Staging System stage II or III disease at study entry, respectively. Patients 
had received a median of 4 prior lines of therapy (range 2 – 9) and 45% of the treated 
patients had received ≥5 prior lines of therapy. All patients had received prior bortezomib 
and corticosteroid therapy, 89% prior thalidomide and/or lenalidomide, 91% alkylating 
agents, 68% anthracyclines and 66% high-dose melphalan with stem cell rescue. Eighty-
three percent of patients had relapsed and refractory disease at the time of study enrollment, 
as defined by less than a minimal response to their last therapy (43%) or disease progression 
within 60 days of their last treatment (40%). Of the 50 patients previously treated with 
dexamethasone, 70% were refractory to their last dexamethasone-containing therapy. 
Baseline characteristics were similar between patients on treatment plans A and B, although 
a higher proportion of patients on treatment plan B had relapsed and refractory disease 
(P=0.2218), as well as disease refractory to their last dexamethasone-containing regimen 
(P=0.0031).
Pharmacokinetic, pharmacodynamic and immunogenicity analyses
The similar mean siltuximab concentrations (±standard deviation) of 44.81 μg/ml (±15.21) 
and 44.51 μg/ml (±19.80) for patients on day 8 of cycle 1 on treatment plans A and B, 
respectively, suggest that dexamethasone did not impact siltuximab pharmacokinetics. 
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Antibodies to siltuximab were not detected in any of the 36 patients who had appropriate 
samples for evaluation. Mean CRP levels promptly decreased by cycle 1, day 15 and reached 
the lower limit of quantification (0.2 mg/l) by cycle 2, day 15 (Fig 1) for all treated patients. 
A linear mixed effect model, with the patient identifier as a random effect and the visit as a 
fixed effect, was fitted on the data (number of patients per visit >12). The CRP value was 
significantly different on all visits after cycle 1 day 1 compared with cycle 1 day 1 
(P<0.04).The random effect showed 4 outliers; when these were removed, the P-values 
dropped even lower (P<10−6) for all visits. Hepcidin is a 25 kD peptide that plays a critical 
role in iron homeostasis and is also induced by IL6 (Nemeth, et al 2004). Mean hepcidin 
levels ±standard deviation dropped from 240.33 ng/ml ± 327.00 at cycle 1, day 1 to 195.20 
ng/ml ± 271.86 at cycle 2, day 1 and 104.36 ng/ml ± 92.06 at cycle 3, day 1. The same 
statistical analysis was also applied to the hepcidin values with the following results: no 
significant changes were detected between cycle 2 day 1 and cycle 1 day 1 (P=0.5243). The 
difference between cycle 3 day 1 and cycle 1 day 1 was larger, but did not reach the 
significance threshold (P=0.0602).
Efficacy
The median duration of study follow-up was 13.9 months (range 0.5 – 37.7). Thirteen 
patients on treatment plan A and 38 on treatment plan B were evaluable for response. There 
were no responses to single-agent siltuximab, with 8 patients achieving stable disease and 5 
disease progression. The overall response rate (≥partial response rate) per EBMT criteria for 
those on treatment plan B was 8% (95% confidence interval 2% − 21%), with 8% of patients 
achieving a minimal response as their best response and 68% stable disease (Table II). Of 
the 9 evaluable patients on treatment plan A who had dexamethasone added to siltuximab 
therapy for lack of response, 5 achieved a partial response. Thus, the overall response rate 
for patients receiving combination therapy on either plan A or B was 17% (8 patients, 95% 
confidence interval 8% − 31%). No very good partial or complete responses were seen. Of 
the 8 patients achieving a partial response on combination therapy, 7 had disease that was 
refractory to their most recent line of therapy. The median time to response was 1.6 months 
(range 0.7 – 8.1 months) and the median duration of response 5.9 months (95% confidence 
interval 4.8 – 12 months). The clinical benefit rate (≥minimal response rate) for patients 
receiving combination therapy was 23%. Utilizing updated IMWG uniform response 
criteria, the clinical benefit rate for patients receiving combination therapy was 28%.
Given the role of IL6 in corticosteroid resistance, we evaluated the efficacy of siltuximab 
and dexamethasone for those patients with previously documented resistance to 
dexamethasone-based therapy. Five of 32 evaluable patients (16%) with disease refractory to 
their most recent dexamethasone-containing therapy had ≥minimal response with siltuximab 
and dexamethasone, whereas 5 of 12 evaluable patients (42%) with disease sensitive to their 
last dexamethasone-based regimen responded (P=0.1054). Additionally, of 10 patients with 
a minimal or partial response, 7 had less than a minimal response to a prior dexamethasone-
based therapy.
The median time to progression for patients receiving combination siltuximab and 
dexamethasone was 4.4 months (Fig 2A, 95% confidence interval 2.8 – 5.6 months). The 
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median progression-free and overall survival was 3.7 months (95% confidence interval 2.8 – 
4.9 months) and 20.4 months (Fig 2B, 95% confidence interval 11.4 – 32.3 months) for 
patients receiving combination therapy.
Safety
Fifty-three patients received at least 1 dose of siltuximab and were evaluable for safety. All 
49 patients who received combination therapy experienced at least 1 adverse event, with 
90% and 92% of patients experiencing adverse events at least reasonably related to 
siltuximab and dexamethasone, respectively. Haematological toxicity was common with 
neutropenia, anaemia and thrombocytopenia occurring in 29%, 35% and 49% of patients, 
respectively (Table III). However, grade 3 or 4 neutropenia was only seen in 15% and 3% 
and grade 3 or 4 thrombocytopenia in 14% and 12% of patients, respectively. No episodes of 
febrile neutropenia occurred. Common non-haematological toxicities included fatigue 
(43%), abnormal hepatic function (31%), diarrhoea and peripheral oedema (29% each), 
dyspnea (27%), dizziness (25%), nausea and insomnia (22% each), constipation and weight 
increase (20% each), and myalgia and enzyme abnormality (16% each). 
Hypertriglyceridaemia has been seen with the anti-IL6 receptor monoclonal antibody, 
tocilizumab (Maini, et al 2006). In the present study, 7 patients (14%) experienced 
hypertriglyceridaemia; all but 1 episode was less than grade 3 in severity. Only 2 patients 
treated with combination therapy had an infusion-related reaction, both of which were 
≤grade 2 in severity. No venous thromboembolic events occurred. Fifty-seven percent of 
patients who received combination therapy had 1 or more infection-related adverse events 
that included upper respiratory infections (14%), cellulitis, oral candidiasis, and pneumonia 
(8% each), herpes zoster reactivation and urinary tract infection (6% each), and septic shock 
(4%). One patient had reactivation of hepatitis B. In total, 12% and 6% of patients 
experienced grade 3 or 4 infections, respectively.
Seventy-four percent of patients receiving combination therapy had ≥grade 3 adverse events. 
In addition to the ≥grade 3 haematological and infection-related adverse events noted above, 
common ≥grade 3 adverse events included fatigue and abnormal hepatic function (8% each). 
Grade 4 events occurred in 29% of patients, whereas serious adverse events were noted in 
41% of patients. Forty-one percent of patients on combination therapy required temporary 
withholding of siltuximab due to adverse events, while 47% of patients had dexamethasone 
held or dose reduced due to adverse events. Adverse events necessitating discontinuation of 
therapy occurred in 12 (25%) of the 49 patients treated with siltuximab and dexamethasone, 
but no single event accounted for discontinuation in more than 2 patients. Five patients died 
during the study period; 3 due to disease progression and 2 due to infection, one of which 
was felt to be reasonably attributable to protocol therapy.
Discussion
We evaluated the safety and efficacy of siltuximab with or without dexamethasone for 
patients with relapsed or refractory multiple myeloma. Unfortunately, no responses were 
seen in the first 14 evaluable patients treated with single-agent siltuximab, with the caveat 
that a response to monotherapy would have been difficult to discern given the introduction of 
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dexamethasone within the first 2 cycles for lack of response. This is in contrast to the phase 
1 study of single-agent siltuximab in patients with multiple myeloma, B-cell non-Hodgkin 
lymphoma or Castleman disease in which 2 of 13 patients with multiple myeloma achieved 
complete responses on siltuximab (Kurzrock, et al 2011). Although the overall response rate 
to combination siltuximab and dexamethasone in treatment plan B was only 8%, the overall 
response rate was 17% for all patients treated with siltuximab and dexamethasone 
combination therapy. Moreover, the clinical benefit rate (≥minimal response rate) was 23%. 
When using the updated international uniform response criteria, the clinical benefit rate was 
28%. The median time to progression and overall survival for patients receiving combination 
therapy was 4.4 and 20.4 months, respectively, with better outcomes seen for those with 
responsive disease.
Several factors may have contributed to the modest response rate of combination siltuximab 
and dexamethasone in this study. First, multiple myeloma becomes increasingly independent 
of the bone marrow microenvironment for survival in the relapsed/refractory setting, which 
in part explains the increased incidence of extramedullary disease over time. Additionally, 
mutations inherent to the myeloma cells may confer corticosteroid resistance. A salient 
example is the presence of RAS mutations in advanced multiple myeloma that in pre-clinical 
models lead to dexamethasone resistance (Rowley, et al 2000). As such, anti-IL6 therapy 
may be better positioned earlier in the course of the disease. Second, although systemic IL6 
inhibition in the present study was readily apparent, as demonstrated by a decrease in serum 
CRP levels, IL6 inhibition at the tumoural level may have been suboptimal. In the above-
mentioned phase 1 study of siltuximab monotherapy, radiological responses were seen in 8 
of 11 patients with Castleman disease treated at the highest dose of 12 mg/kg once every 2 
or 3 weeks (van Rhee, et al 2010). The 2 patients with multiple myeloma who achieved 
complete responses to single-agent therapy in the phase 1 study were also treated at a higher 
siltuximab dose intensity, utilizing either 6 mg/kg weekly or 12 mg/kg once every 3 weeks 
(unpublished observations). Notably, there was a higher response rate seen in patients on 
treatment plan A of this study compared with those on treatment plan B. CRP levels were 
not maximally inhibited until cycle 2, day 15. As such, it is tempting to speculate that the 
improved response rate in treatment plan A was the result of more optimal IL6 inhibition at 
the time that dexamethasone was introduced. However, it should be noted that a smaller 
proportion of patients on treatment plan A had disease refractory to their last 
dexamethasone-containing therapy, which could readily explain the difference. Nonetheless, 
given the fact that patients had received a median of 4 prior lines of therapy and 83% had 
relapsed and refractory disease, the 17% overall response rate and 23% clinical benefit rate 
seen in this study are noteworthy.
Interestingly, responses were seen in patients with multiple myeloma refractory to their last 
dexamethasone-based therapy, suggesting the possibility that inhibition of IL6 signalling 
with siltuximab can overcome corticosteroid resistance in some instances. This would 
support data from a large body of pre-clinical work demonstrating the ability to restore 
corticosteroid sensitivity via anti-IL6 therapy (Cheung and Van Ness 2001, Fulciniti, et al 
2009, Grigorieva, et al 1998, Honemann, et al 2001, Voorhees, et al 2009). However, we 
cannot rule out the possibility that differences in response to dexamethasone-based therapy 
were due to differences in dexamethasone dose intensity between regimens, as this level of 
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information could not be readily established from the medical records. We are also limited 
by the lack of a true control arm that would enable us to distinguish the role of siltuximab in 
the observed response rates. Certainly, randomized studies are needed to determine if 
siltuximab can overcome corticosteroid resistance.
Although haematological toxicity was common, grade 3 and 4 haematological adverse 
events were infrequent. Our results are in line with those from the phase 1 study of 
siltuximab, in which grade 3 or higher possibly related neutropenia and thrombocytopenia 
were seen in only 16% and 4% of patients, respectively (unpublished observations). Non-
haematological toxicities were largely in line with expected toxicities of dexamethasone 
(e.g. fatigue, peripheral oedema, dizziness, myalgias, insomnia, and weight increase). 
However, infections occurred at a high rate, with grade 3 and 4 infections seen in 12% and 
6% of patients, respectively. Two patients died of sepsis, one of which was attributed to 
protocol therapy. Certainly, infection-related complications are common in patients with 
advanced multiple myeloma, and high-dose pulse dexamethasone is immunosuppressive in 
and of itself. However, IL6 does play a critical role in immunity and could potentially further 
increase risk. Results from a randomized phase 2 study of bortezomib versus bortezomib 
and siltuximab were recently presented (Orlowski, et al 2012) and did not demonstrate a 
difference in grade 3 or higher infections between the two treatment arms (14% and 16%, 
respectively). Nonetheless, careful attention to infection-related toxicity with siltuximab-
based therapy will be critical moving forward.
In conclusion, the combination of siltuximab and dexamethasone had clinical activity in 
heavily-pretreated multiple myeloma, including patients with relapsed and refractory 
disease. Responses were seen in dexamethasone-refractory disease, suggesting that 
siltuximab may be able to overcome corticosteroid resistance in some cases. Randomized 
studies incorporating siltuximab into current multiple myeloma therapy will be needed to 
better establish its role in therapy, with careful attention to infection-related toxicity. In this 
regard, a randomized phase 2 clinical trial of melphalan, prednisone and bortezomib with or 
without siltuximab at optimal dose intensity is being conducted in newly-diagnosed multiple 
myeloma and should better determine the role of IL6 inhibition in multiple myeloma 
therapy.
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Mean serum C-reactive protein (CRP) concentrations by visit in treated patients. C: cycle. 
SCR: screening. SD: standard deviation.
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Kaplan-Meier curves for (A) time to progression and (B) overall survival in combination-
treated patients. Time-to-event analyses for those on treatment plan A were measured from 
the start of dexamethasone therapy.
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Table I
Baseline patient demographics, disease characteristics and treatment history
Treatment Plan A 
(N=14)
Treatment Plan B 
(N=39)
Treatment Plans A and 
B (N=53)
Median age, years (range) 62 (48 – 89) 65 (43 – 83) 65 (43 – 89)
Sex, N (%)
 Male 7 (50) 23 (59) 30 (57)
 Female 7 (50) 16 (41) 23 (43)
Race (%)
 Caucasian 8 (57) 28 (72) 36 (68)
 Black 2 (14) 5 (13) 7 (13)
 Asian 0 3 (8) 3 (6)
 Other 4 (29) 3 (8) 7 (13)
ECOG Performance Status score, N (%)
 0 5 (36) 10 (26) 15 (28)
 1 8 (57) 26 (67) 34 (64)
 2 1 (7) 3 (8) 4 (8)
Median time from diagnosis, years (range) 4.1 (2.4 – 12.8) 3.9 (0.7 – 13.2) 4.0 (0.7 – 13.2)
Ig isotype, N (%)
 IgG 8 (57) 26 (67) 34 (64)
 IgA 5 (36) 7 (18) 12 (23)
 Light chain 0 5 (13) 5 (9)
International Staging System stage at baseline, N (%)
 I 4 (31) 14 (36) 18 (35)
 II 4 (31) 15 (39) 19 (37)
 III 5 (39) 10 (26) 15 (29)
Median creatinine clearance, ml/min (range) 62 (45 – 179) 70 (27 – 168) 67 (27 – 179)
Relapsed and refractory disease, N (%) 10 (71) 34 (87) 44 (83)
 PD on last prior therapy 6 (43) 14 (36) 20 (38)
 SD on last prior therapy 0 3 (8) 3 (6)
 PD within 60 days of last prior therapy 4 (29) 17 (44) 21 (40)
Refractory to last dexamethasone-based therapy, N/total 
(%)
4/12 (33) 31/38 (82) 35/50 (70)
Median prior lines of therapy, (range) 4 (2 – 8) 4 (2 – 9) 4 (2 – 9)
≥5 prior lines of therapy, N (%) 5 (36) 19 (49) 24 (45)
Prior treatment regimens, N (%)
 Bortezomib 14 (100) 39 (100) 53 (100)
 Corticosteroids 14 (100) 39 (100) 53 (100)
 IMiDs 12 (86) 35 (90) 47 (89)
 Alkylating agents 14 (100) 34 (87) 48 (91)
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Treatment Plan A 
(N=14)
Treatment Plan B 
(N=39)
Treatment Plans A and 
B (N=53)
 Anthracyclines 10 (71) 26 (67) 36 (68)
 ASCT 8 (57) 27 (69) 35 (66)
ASCT: Autologous stem cell transplantation. ECOG: Eastern Cooperative Oncology group. Ig: Immunoglobulin. IMiDs: Immunomodulatory 
drugs. PD: Progressive disease. SD: Stable disease. Percentages may not sum correctly due to rounding.
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Table II
Response assessment of siltuximab with and without dexamethasone
Treatment Plan A
Siltuximab
Treatment Plan B 
(Siltuximab + 
Dexamethasone)
Combination Siltuximab + 
Dexamethasonea
Before Dex After Dex
Evaluable for response, N 13 9 38 47
Overall response rate (≥PR), N (%)
 PR by EBMT 0 (0) 5 (56) 3 (8) 8 (17)
 PR by IMWG 0 (0) 5 (56) 4 (11) 9 (19)
Clinical Benefit Rate (≥MR), N (%)
 PR + MR by EBMT 0 (0) 5 (56) 6 (16) 11 (23)
 PR +MR by IMWG 0 (0) 5 (56) 8 (21) 13 (28)
Stable disease by EBMT, N (%) 8 (62) 1 (11) 26 (68) 27 (57)
Disease progression, N (%) 5 (39) 2 (22) 6 (16) 8 (17)
Time to response (months), median 
(range)
N/A 1.7 (0.7 – 8.1) 1.5 (0.7 – 1.6) 1.6 (0.7 – 8.1)
Duration of response (months), median 
(95% CI)
N/A 12.0 (3.0 – 16.6) 5.9 (4.9 – 9.9) 5.9 (4.8 – 12.0)
CI: Confidence interval. Dex: Dexamethasone. EBMT: European Group for Blood and Marrow Transplantation. IMWG: International Myeloma 
Working Group Criteria. MR: Minimal response. N/A: Not applicable. PR: Partial response.
a
Includes patients in Treatment Plan A who received siltuximab plus dexamethasone and all patients in Treatment Plan B.
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